Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs). This is an ASCO Meeting Abstract from the 2021 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback